Cellular Regulation Of Receptor Signalling And Cytokine Responses
Funder
National Health and Medical Research Council
Funding Amount
$859,288.00
Summary
Cell surface receptors and signalling pathways elicit the release of cytokines, or chemical messengers, to control inflammation, which is the body’s response to infection or danger. We have discovered a new signalling pathway that can turn off inflammation and help prevent inflammatory disease. Our studies will now define the molecular details of this pathway and show how new and existing drugs targeting this pathway can be optimally used to treat inflammation and cancer.
Structural And Functional Characterisation Of The Oncogene P-Rex1
Funder
National Health and Medical Research Council
Funding Amount
$623,447.00
Summary
The spread of cancer to other parts of the body (metastasis) is a major cause of mortality. The characterisation of proteins that regulate metastasis is therefore a priority. P-Rex1 plays a crucial role in promoting metastasis in breast and other cancers. We will determine the structural basis of P-Rex1 activity, and investigate how its dysregulation promotes aberrant cell growth. This study will provide the knowledge to build future drug development programs targeting P-Rex1 in cancer.
Debilitating anxiety disorders, such as post-traumatic stress disorder or panic disorder, affect 14% of adult Australians and current therapy is often ineffective. The amygdala is a brain region that is key to learning fear responses but also in reducing our fear responses. This project will determine whether the brain’s own endogenous opioids can modify the activity of the amygdala in order to provide new leads for novel pharmacotherapies with enhanced efficacy.
Mechanisms Of Ligand-Selective Signalling By Chemokine Receptors
Funder
National Health and Medical Research Council
Funding Amount
$749,428.00
Summary
Receptors are molecules located on the surfaces of cells. They control the response of one cell to chemical signals emitted by different cells. In this project we aim to characterise and understand the molecular details of how a receptor can respond differently to distinct chemical signals. The results of this study will help to guide future development of medicines to control white blood cell migration into tissues during inflammatory diseases such as heart disease, diabetes and arthritis.
Small Molecule Activators Of Glucagon-like Peptide Receptor
Funder
National Health and Medical Research Council
Funding Amount
$658,152.00
Summary
This project seeks new knowledge about (i) a protein on pancreatic cells that can be stimulated to treat problems associated with type 2 diabetes, and (ii) how to create small molecules that can act on this protein and afford a better treatment for diabetes. Advantages of such a new treatment will be low cost, easy administration as an oral tablet rather than injection, need for minimal supervision and monitoring by medical professionals, and therefore more accessibility to global populations.
Elucidating The Mechanisms Of Alpha-conotoxin-induced Calcium Channel Inhibition Via G Protein-coupled Receptors
Funder
National Health and Medical Research Council
Funding Amount
$419,082.00
Summary
N-type voltage-gated calcium channels (VGCCs) are membrane proteins involved in neurotransmission and play a major role in pain. VGCCs are a well-established target for the development of analgesics. Our recent research identified that VGCCs can be inhibited by ?-conotoxins from the venom of marine snails by targeting ?-aminobutyric acid receptors in sensory neurons. We will characterize this novel form of modulation of VGCCs by ?-conotoxins and define the pathways that lead to VGCC inhibition.
The hormone angiotensin II (AngII) contributes broadly to the cardiovascular, endocrine, neural and metabolic systems. It binds to the angiotensin II type 1 (AT1) receptor and inappropriate activity leads to hypertension. Using a range of molecular and biophysical approaches and the angiotensin receptor as a model GPCR, we will study the role of the cell membrane in AT1 activation which may lead to new approaches for drug design.
This project will investigate the properties of an important family of proteins that play a major role in diseases such as chronic pain and cardiovascular illnesses. It will apply multidisciplinary, cutting-edge, approaches to understand how different types of drugs act on these proteins, and use this information to develop novel drug leads that can modulate these proteins in a more selective and efficacious manner, with a particular emphasis on targeting chronic pain conditions.
The Importance Of Receptor Trafficking For Signalling Of Pain And Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$787,604.00
Summary
Inflammation and pain are normal processes that are essential for survival: inflammation fights infections and pain allows avoidance of danger. These processes are normally tightly controlled and are transient. During disease, they become dysregulated and chronic. By understanding the normal processes of inflammation and pain, and by determining how dysregulation causes disease, we aim to develop new treatments for diseases that are a major cause of human suffering.
Engendering Biased Signalling At The Human Calcium Sensing Receptor (CaSR) To Correct Pathophysiology
Funder
National Health and Medical Research Council
Funding Amount
$633,860.00
Summary
The human calcium sensing receptor (CaSR) has been targeted therapeutically in hyperparathyroidism and osteoporosis, but current CaSR therapeutics exhibit problematic side effects or are ineffective. Thus, the current research proposal seeks to understand the specific properties of CaSR drugs required to selectively control whole body calcium and bone mineral metabolism, to identify ligands that can mediate desired therapeutic effects at the exclusion of adverse effects.